CStone Pharmaceuticals
PH4
Company Profile
Business description
CStone Pharmaceuticals is engaged in developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment. The Group has been operating in one reportable segment, being the research and development of high-complex biopharmaceutical products, the sale of pharmaceutical products, and provide license of its IP or commercialisation licenses to customers.
Contact
218 Xinghu Street
C1 Building, North Block
Suzhou Industrial Park
Suzhou215123
CHNT: +86 51287186550
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
147
Stocks News & Analysis
stocks
3 charts on Anthropic’s historic IPO filing
As Anthropic prepares to sell stock to the public, the S-1 reveals important information for investors on revenue growth, profitability, and adoption.
stocks
Weight loss drugs not an existential threat to undervalued ASX share
A durable growth story despite GLP-1 headwinds.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,981.10 | 12.30 | 0.14% |
| CAC 40 | 7,887.14 | 39.82 | 0.51% |
| DAX 40 | 25,590.77 | 179.93 | 0.71% |
| Dow JONES (US) | 52,377.57 | 15.99 | 0.03% |
| FTSE 100 | 10,686.54 | 80.79 | -0.75% |
| HKSE | 23,033.23 | 8.09 | -0.04% |
| NASDAQ | 26,477.81 | 308.43 | 1.18% |
| Nikkei 225 | 64,067.10 | 798.73 | 1.26% |
| NZX 50 Index | 13,719.48 | 39.21 | 0.29% |
| S&P 500 | 7,722.60 | 45.83 | 0.60% |
| S&P/ASX 200 | 8,856.60 | 6.50 | 0.07% |
| SSE Composite Index | 3,657.90 | 9.60 | 0.26% |